Author Archive for: DaveDias

“Threat clears a man’s head”
Robert F. Dees
Major General (Retired), U.S. Army

Two of life’s biggest questions that everyone should ask and answer are these:

Why am I here?
What happens to me when I die?

Steve Jobs, Co-Founder and CEO of Apple Computer provokes our thinking and declares that “death is the greatest invention of life”

Certainly on Irene’s Journey of Faith we have asked and answered those questions in a plethora of ways and in the most surreal of circumstances.

Irene logs her vital statistics and monitors the Hemodialysis.  She was attended today by Elsa, the Satellite Dialysis Technician.

If you’re not contemplating why you’re here (which defines PURPOSE) and if you’re not ruminating on the question “what happens to me when I die?”, (which construes ETERNAL destination) then, according to Major General Bob Dees, perhaps there’s not enough threat to clear your head.

Caminando con Fé

Dave

Continue reading

We had a surprise call from Ron and Debbie Richards who treated us to breakfast at the Dolphin Restaurant on the Santa Cruz Wharf.  Ron was my best man in our wedding and I was his.  I went to high school with Ron and Deb.  We had a great time together!!!

Continue reading

Recently several people have inquired as to Irene’s stem cell tranplant process.  Her process was an autologous and below is a detailed explanation.  Below that is a LINK that offers even greater infomation.

Autologous HSCT requires the extraction (Apheresis) of haematopoietic stem cells (HSC) from the patient and storage of the harvested cells in a freezer. The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient’s malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient’s bone marrow function to grow new blood cells). The patient’s own stored stem cells are then returned to his/her body, where they replace destroyed tissue and resume the patient’s normal blood cell production. Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment since the recovery of immune function is rapid. Also, the incidence of patients experiencing rejection (graft-versus-host disease) is very rare due to the donor and recipient being the same individual. These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. However, for others such as Acute Myeloid Leukemia, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, and therefore the allogeneic treatment may be preferred for those conditions. Researchers have conducted small studies using non-myeloablative hematopoietic stem cell transplantation as a possible treatment for type I (insulin dependent) diabetes in children and adults. Results have been promising; however, at the time of this writing, it is premature to speculate as to whether these experiments will lead to effective treatments for diabetes.

http://en.wikipedia.org/wiki/Stem_cell_transplant

More detail is available about the early days of Irene’s treatment protocol (May/June, 2007) by scrolling to the earliest dates of this BLOG or reading the book, Irene’s Journey of Faith.

Thanks for caring,
Dave

Continue reading